- Home
- AVTE
as 03-28-2025 4:00pm EST
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 72.5M | IPO Year: | 2021 |
| Target Price: | $11.75 | AVG Volume (30 days): | 64.1K |
| Analyst Decision: | Hold | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.25 - $32.42 | Next Earning Date: | 03-27-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Aerovate Therapeutics Inc. News
AVTE Breaking Stock News: Dive into AVTE Ticker-Specific Updates for Smart Investing
BioPharma Dive
5 months ago
Jade, another biotech spinout of Paragon, to merge with Aerovate
GlobeNewswire
5 months ago
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
MT Newswires
9 months ago
Aerovate Therapeutics to Explore Strategic Alternatives After Hypertension Trial Shutdown
BioPharma Dive
9 months ago
Ligand to buy Apeiron; Roche reports another TIGIT setback
GlobeNewswire
9 months ago
Aerovate Therapeutics to Explore Strategic Alternatives
Clinical Trials Arena
9 months ago
Aerovate slashes workforce after failed Phase IIb trial
Zacks
9 months ago
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals
MT Newswires
9 months ago
--Guggenheim Downgrades Aerovate Therapeutics to Neutral From Buy
Compare AVTE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AVTE Aerovate Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.